| Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes BO Ahrén, E Simonsson, H Larsson, M Landin-Olsson, H Torgeirsson, ... Diabetes care 25 (5), 869-875, 2002 | 582 | 2002 |
| Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes … B Littorin, P Blom, A Schölin, HJ Arnqvist, G Blohme, J Bolinder, ... Diabetologia 49, 2847-2852, 2006 | 406 | 2006 |
| Fat cell enlargement is an independent marker of insulin resistance and ‘hyperleptinaemia’ M Lundgren, M Svensson, S Lindmark, F Renström, T Ruge, JW Eriksson Diabetologia 50, 625-633, 2007 | 385 | 2007 |
| Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs … KI Birkeland, ME Jørgensen, B Carstensen, F Persson, HL Gulseth, ... The lancet Diabetes & endocrinology 5 (9), 709-717, 2017 | 379 | 2017 |
| Regional differences of insulin action in adipose tissue: insights from in vivo and in vitro studies F Giorgino, L Laviola, JW Eriksson Acta Physiologica Scandinavica 183 (1), 13-30, 2005 | 346 | 2005 |
| Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled … JW Eriksson, P Lundkvist, PA Jansson, L Johansson, M Kvarnström, ... Diabetologia 61, 1923-1934, 2018 | 342 | 2018 |
| Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised … P Dandona, C Mathieu, M Phillip, L Hansen, SC Griffen, D Tschöpe, ... The lancet Diabetes & endocrinology 5 (11), 864-876, 2017 | 307 | 2017 |
| The incidence of type I diabetes has not increased but shifted to a younger age at diagnosis in the 0–34 years group in Sweden 1983 to 1998 A Pundziute-Lyckå, G Dahlquist, L Nyström, H Arnqvist, E Björk, G Blohme, ... Diabetologia 45, 783-791, 2002 | 295 | 2002 |
| Early glycemic control, age at onset, and development of microvascular complications in childhood-onset type 1 diabetes: a population-based study in northern Sweden M Svensson, JW Eriksson, G Dahlquist Diabetes care 27 (4), 955-962, 2004 | 294 | 2004 |
| The risk of venous thromboembolism is markedly elevated in patients with diabetes V Petrauskiene, M Falk, I Waernbaum, M Norberg, JW Eriksson Diabetologia 48, 1017-1021, 2005 | 285 | 2005 |
| Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial O Mosenzon, TM Blicher, S Rosenlund, JW Eriksson, S Heller, OH Hels, ... The lancet Diabetes & endocrinology 7 (7), 515-527, 2019 | 264 | 2019 |
| Emerging role of SGLT-2 inhibitors for the treatment of obesity MJ Pereira, JW Eriksson Drugs 79 (3), 219-230, 2019 | 264 | 2019 |
| The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS) M Henricsson, L Nyström, G Blohme, JAN Ostman, C Kullberg, ... Diabetes care 26 (2), 349-354, 2003 | 248 | 2003 |
| Metabolic stress in insulin’s target cells leads to ROS accumulation–a hypothetical common pathway causing insulin resistance JW Eriksson FEBS letters 581 (19), 3734-3742, 2007 | 239 | 2007 |
| Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes M Lundgren, J Burén, T Ruge, T Myrnas, JW Eriksson The Journal of Clinical Endocrinology & Metabolism 89 (6), 2989-2997, 2004 | 237 | 2004 |
| Dexamethasone impairs insulin signalling and glucose transport by depletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B in primary … J Burén, HX Liu, J Jørsen, JW Eriksson European Journal of Endocrinology 146 (3), 419-429, 2002 | 235 | 2002 |
| Postprandial hypertriglyceridemia and insulin resistance in normoglycemic first-degree relatives of patients with type 2 diabetes M Axelsen, U Smith, JW Eriksson, MR Taskinen, PA Jansson Annals of internal medicine 131 (1), 27-31, 1999 | 227 | 1999 |
| Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study P Dandona, C Mathieu, M Phillip, L Hansen, D Tschöpe, F Thorén, J Xu, ... Diabetes Care 41 (12), 2552-2559, 2018 | 224 | 2018 |
| Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl … F Persson, T Nyström, ME Jørgensen, B Carstensen, HL Gulseth, ... Diabetes, Obesity and Metabolism 20 (2), 344-351, 2018 | 221 | 2018 |
| Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM E CARVALHO, PERA JANSSON, M AXELSEN, JW Eriksson, X HUANG, ... The FASEB Journal 13 (15), 2173-2178, 1999 | 196 | 1999 |
